

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



開拓藥業有限公司*

KINTOR PHARMACEUTICAL LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9939)

**VOLUNTARY ANNOUNCEMENT
FIRST SUBJECT DOSING IN PHASE I CLINICAL TRIAL OF GT20029
(AR-PROTAC) IN THE UNITED STATES**

This is a voluntary announcement made by Kintor Pharmaceutical Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors (the “**Director(s)**”) of the Company (the “**Board**”) is pleased to announce that on 1 February 2022 local time, the first subject has been enrolled and dosed in the phase I clinical trial of GT20029 for the treatment of androgenetic alopecia (AGA) and acne in the United States (the “**Clinical Trial**”).

The Clinical Trial is a randomised, double-blind, placebo-controlled, parallel group, dose escalation study to evaluate the safety, tolerability, and pharmacokinetics (PK) of GT20029 (gel) following single ascending dose in healthy subjects and multiple ascending dose administration in subjects with AGA or acne.

GT20029 is a topical androgen receptor (“**AR**”) compound developed by using the Group’s inhouse Proteolysis Targeting Chimera (“**PROTAC**”) platform. To the best of the Company’s knowledge, GT20029 is the first topical PROTAC compound globally to enter the clinical stage. Center for Drug Evaluation (CDE) of the National Medical Products Administration of China (NMPA) and the U.S. Food and Drug Administration (FDA) approved GT20029’s phase I clinical trial for treating AGA and acne vulgaris subjects in April 2021 and July 2021 respectively. On 28 July 2021, the first batch of subjects were dosed in the phase I clinical trial of GT20029 in China. For further details, please refer to the announcements of the Company dated 15 April 2021, 13 July 2021 and 28 July 2021.

Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that GT20029 will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED

Dr. Youzhi Tong

Chairman of the Board, Executive Director and Chief Executive Officer

Hong Kong, 3 February 2022

As of the date of this announcement, the executive Directors are Dr. Youzhi Tong and Ms. Yan Lu; the non-executive Directors are Mr. Weipeng Gao, Dr. Yan Wang and Ms. Geqi Wei; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

* *For identification purpose only*